Drug Database
Back to search

Netherlands· NL-5a1f8032ffc7

Veltassa 8,4 g, poeder voor orale suspensie

A patiromer calcium product containing copolymeer van calcium sorbitol 2-fluoroacrylzuur, divinylbenzeen, 1,7-octadieen (91-4-5), registered in Netherlands by Vifor Fresenius Medical Care Renal Pharma France. The same ATC class is registered in 12 of our 19 countries.

ATC V03AE09

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedVeltassa 8,4 g, poeder voor orale sus…ATCV03AE09REGISTER NO.NL-5a1f8032ffc7PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about copolymeer van calcium sorbitol 2-fluoroacrylzuur, divinylbenzeen, 1,7-octadieen (91-4-5)Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Patiromer calcium is registered in 12 of 19 countries.

Countries holding a registration under ATC V03AE09 (patiromer calcium), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 7 of them publish a price we can compare per daily dose
Search patiromer calcium products by name

Patiromer calcium · ATC V03AE09

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of patiromer calcium costs, country by country.

Normalised to the WHO defined daily dose (8.4 g), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Patiromer calcium · price per daily dose (8.4 g)

USD · FX 28 Sept 2026

  • CH Switzerland$8.39
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
COPOLYMEER VAN CALCIUM SORBITOL 2-FLUOROACRYLZUUR, DIVINYLBENZEEN, 1,7-OCTADIEEN (91-4-5)
Manufacturer
Vifor Fresenius Medical Care Renal Pharma France
Country
Netherlands (NL)
ATC code
V03AE09
ATC class
Patiromer calcium
Defined daily dose
8.4 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/17/1179

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

69 interactions on record for patiromer calcium.

Graded by severity as the source publishes them — 12 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check patiromer calcium against other medicinesHow interaction checks work

Patiromer calcium · interactions on record

69 records

  • 12 severe
  • 57 moderate

Most severe, free to view

  • Magnesium carbonateA02AA01severe
  • Magnesium oxideA02AA02severe
  • Magnesium hydroxideA02AA04severe
  • Kombinationen von AluminiumsalzenA02AB10severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same class

Other records under V03AE09

Patiromer calcium, as other registers publish it.

All patiromer calcium products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cf2d6b70-4bf3-478d-9d3c-69553b46390c
GET /v1/drugs/cf2d6b70-4bf3-478d-9d3c-69553b46390c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Poeder voor orale suspensie",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/veltassa-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Patiromer calcium",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp119222",
  "excipients": [
    "ARABISCHE GOM (E 414)"
  ],
  "substances": [
    "COPOLYMEER VAN CALCIUM SORBITOL 2-FLUOROACRYLZUUR, DIVINYLBENZEEN, 1,7-OCTADIEEN (91-4-5)"
  ],
  "leaflet_url": null,
  "authorised_at": "2017/07/19",
  "procedure_number": "EMEA/H/C/004180",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/17/1179",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about patiromer calcium.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console